Drugs / VF001-DP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02973893 | Nov 2016 → Nov 2018 | ulcer disease, ulcer of lower limbs, vascular disorder | Factor Therapeutics Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VF001-DP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02973893 ↗ |
| Modality | Protein / enzyme biologic | “VF001-DP contains parts of normal vitronectin and Insulin-like growth factor 1 (IGF-I) combined in a single protein.” NCT02973893 ↗ |